Intercept's Pricing Of Ocaliva Anticipates Outcomes Data
This article was originally published in The Pink Sheet Daily
Executive Summary
With OCA approved for primary biliary cholangitis, Intercept anticipates a potentially slow ramp of sales, but has priced product at $69,350 a year based on need in second-line treatment and in anticipation of survival benefit data.